Noninvasive, Stool DNA-Based Colon Cancer Screening Test Is Now Covered By Medicare

Cologuard_Box

In a release issued earlier this month, the Center for Medicare & Medicaid Services (CMS) issued its final National Coverage Determination (NCD) for Cologuard®, making it the first and only Food and Drug Administration (FDA) approved stool DNA test for the detection of colorectal cancer and precancer covered by Medicare.

Medicare coverage for Cologuard will go into effect immediately, and the hope is that this noninvasive colon cancer screening test will reach those 23 million Americans who have not yet undergone their life-saving screening.

The final NCD can be found online here: http://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=277

Other News From Around the Web

  • Major health system Kaiser Permanente Southern California announced last week a pledge to cut the number of colorectal cancer deaths in half by 2023 through focus on prevention, screening, diagnosis, treatment and survivorship.
  • Researchers from Weill Cornell Medical College in New York City presented new findings on the recent increase in early-onset colon cancer incidence rates at the annual meeting of the American College of Gastroenterology this week.
  • Here's an article on the essential health screening exams you need that can save you a great deal of money in the long run.
  • A new study explores the impact that new technological advances in colonoscopic imaging have on adenoma detection rates.
Get Colon Cancer eBook

Topics: Colon Cancer News